Gene · 27338
Papers1,523
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,523
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. | MedComm (2020) | 2025 | 40740483 | PubTator, text mining | PubMed |
| The P132H mutation of SARS-CoV-2 NSP5 relieves its inhibition on interferon-β activation via blocking MAVS degradation. | Cell Mol Life Sci | 2025 | 40736574 | PubTator, text mining | PubMed |
| TRIM21: a multifaceted regulator in cancer. | Front Cell Dev Biol | 2025 | 40735642 | PubTator, text mining | PubMed |
| Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs. | Commun Chem | 2025 | 40730655 | PubTator, text mining | PubMed |
| Proteome solubility is differentially reshaped by thermal stress and regulators of ubiquitination. | J Biol Chem | 2025 | 40713964 | PubTator, text mining | PubMed |
| Trim45: An emerging E3 ubiquitin ligases in cancer. | Cell Signal | 2025 | 40466841 | PubTator, text mining | PubMed |
| Multiple-omics analysis of aggrephagy-related cellular patterns and development of an aggrephagy-related signature for hepatocellular carcinoma. | World J Surg Oncol | 2025 | 40307857 | PubTator, text mining | PubMed |
| Ubiquitin-proteasome Pathway-linked Gene Signatures as Prognostic Indicators in Prostate Cancer. | Anticancer Res | 2025 | 40295064 | PubTator, text mining | PubMed |
| Activity-based protein profiling reveals both canonical and novel ubiquitin pathway enzymes in Plasmodium. | PLoS Pathog | 2025 | 40249735 | PubTator, text mining | PubMed |
| [Effect of CMTM6 on PD-L1 in Helicobacter pylori infected gastric epithelial cells]. | Beijing Da Xue Xue Bao Yi Xue Ban | 2025 | 40219552 | PubTator, text mining | PubMed |
| Construction of ubiquitination-related risk model for predicting prognosis in lung adenocarcinoma. | Sci Rep | 2025 | 40189665 | PubTator, text mining | PubMed |
| Ubiquitin-conjugating enzyme E2S (UBE2S) as a prognostic biomarker and regulator of tumorigenesis in osteosarcoma. | Int Immunopharmacol | 2025 | 40188527 | PubTator, text mining | PubMed |
| Single cell transcriptomic analysis reveals tumor immune infiltration by macrophage cells gene signature in lung adenocarcinoma. | Discov Oncol | 2025 | 40029500 | PubTator, text mining | PubMed |
| Small molecule targeted protein degradation via the UPS: venturing beyond E3 substrate receptors. | RSC Med Chem | 2025 | 39949641 | PubTator, text mining | PubMed |
| UBE2S, downregulated by miR-152-3p, facilitates prostate cancer progression through the PTEN-mediated AKT/mTOR pathway. | Hum Mol Genet | 2025 | 39807632 | PubTator, text mining | PubMed |
| Reply to correspondence on "UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma". | Clin Mol Hepatol | 2025 | 39104000 | PubTator, text mining | PubMed |
| Correspondence to editorial on "UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL". | Clin Mol Hepatol | 2025 | 39069722 | PubTator, text mining | PubMed |
UBE2S: A novel driver of HIF-1alpha-induced metabolic reprogramming in hepatocellular carcinoma: Editorial on "UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL". | Clin Mol Hepatol | 2025 | 39038959 | PubTator, text mining | PubMed |
| Identification of Tumor-Suppressive miR-30a-3p Controlled Genes: ANLN as a Therapeutic Target in Breast Cancer. | Noncoding RNA | 2024 | 39728605 | PubTator, text mining | PubMed |
| UBC18 E2 conjugating enzyme depends on SINAT1 E3 ligase to destabilize the ESCRT component FREE1 in plant iron deficiency responses. | Plant J | 2024 | 39413228 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/27338/papers?page=3